Please login to the form below
FDA approves Indian Sun's generic AD drug
The US FDA has approved Indian company Sun Pharma's generic equivalent of Forest Laboratory's Alzheimer's disease treatment Namenda
The US Food and Drug Administration (FDA) has approved Indian company Sun Pharma's Abbreviated New Drug Application (ANDA) to market a generic equivalent of Forest Laboratory's Alzheimer's disease (AD) treatment Namenda (memantine). Sun will receive 180 days of sales exclusivity on the drug which will be sold in 5mg and 10mg tablets.
The Mumbai-based company said that 5mg and 10mg strengths of memantine have combined annual sales of around $1.2bn in the US.
Memantine is the first in a novel class of Alzheimer's disease medications, which work by acting on the glutamatergic system, blocking NMDA glutamate receptors.
Memantine is also sold by Merz as Akatinol, by Lundbeck as Ebixa and Abixa and by Unipharm as Memox.
Share
Related Hub content
Subscribe to our email news alerts
- Pfizer’s RSV vaccine granted MHRA approval to protect infants and older adults
- Novavax’s updated COVID-19 vaccine granted Emergency Use Listing by WHO
- FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies
- Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership
- New blood test to reduce heart attacks and death rates in A&E heart patients
- Clairvoyant commercialisation
No results were found
PMHub
Red Thread Market Access Ltd
Blending brilliant writing with in-depth market access and reimbursement expertise...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
